The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten
Open accessAbstract
PTEN is a tumor suppressor gene mutated in various advanced human neoplasias, including glioblastomas and prostate, breast, endometrial, and kidney cancers. This tumor suppressor is a lipid phosphatase that negatively regulates cell survival and proliferation mediated by phosphatidylinositol 3-kinase/protein kinase B signaling. Using the Cre– loxP system, we selectively inactivated Pten in murine tissues in which the MMTV-LTR promoter is active, resulting in hyperproliferation and neoplastic changes in Pten-null skin and prostate. These phenotypes had early onset and were completely penetrant. Abnormalities in Pten mutant skin consisted of mild epidermal hyperplasia, whereas prostates from these mice exhibited high-grade prostatic intraepithelial neoplasia (HGPIN) that frequently progressed to focally invasive cancer. These data demonstrate that Pten is an important physiological regulator of growth in the skin and prostate. Further, the early onset of HGPIN in Pten mutant males is unique to this animal model and implicates PTEN mutations in the initiation of prostate cancer. Consistent with high PTEN mutation rates in human prostate tumors, these data indicate that PTEN is a critical tumor suppressor in this organ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Self-citationWang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland
Li, G., Robinson, G. W., Lesche, R., Martinez-Diaz, H., Jiang, Z., Rozengurt, N., Wagner, K.-U., Wu, D.-C., Lane, T. F., Liu, X., et al. (2002) · Development · doi:10.1242/dev.129.17.4159 · Cited by 272
Self-citation
Cited by
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620
“Mice with PTEN deletion and mutation are highly susceptible to tumor induction and conditional knockout of PTEN leads to neoplasia in multiple organs such as the mammary gland, skin, and prostate (Backman et al., 2004; Li et al., 2002; Suzuki et al., 1998).”
BackgroundMolecular Mechanisms Underlying the Activation of Mammalian Primordial Follicles
Adhikari, D., & Liu, K. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0048 · Cited by 481
Xin, L., Lawson, D. A., & Witte, O. N. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502320102 · Cited by 423
PTEN, more than the AKT pathway
Blanco-Aparicio, C., Renner, O., Leal, J. F. M., & Carnero, A. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm052 · Cited by 403
PTEN: a new guardian of the genome
Yin, Y., & Shen, W. H. (2008) · Oncogene · doi:10.1038/onc.2008.241 · Cited by 388
Solar and ultraviolet radiation
Gies, P., Roy, C., & Udelhofen, P. (2004) · Cancer Prevention — Cancer Causes · doi:10.1007/978-94-017-0511-0_3 · Cited by 354
PI3K/PTEN signaling in tumorigenesis and angiogenesis
Jiang, B.-H., & Liu, L.-Z. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.09.008 · Cited by 345
Akt-regulated pathways in prostate cancer
Majumder, P. K., & Sellers, W. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209096 · Cited by 344
Choi, N., Zhang, B., Zhang, L., Ittmann, M., & Xin, L. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.005 · Cited by 341
Lack of PTEN sequesters CHK1 and initiates genetic instability
Puc, J., Keniry, M., Li, H. S., Pandita, T. K., Choudhury, A. D., Memeo, L., Mansukhani, M., Murty, V. V. V. S., Gaciong, Z., Meek, S. E. M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.009 · Cited by 328
PTEN function in normal and neoplastic growth
Chow, L. M. L., & Baker, S. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.042 · Cited by 275
Carnero, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941865 · Cited by 272
Arcaro, A., & Guerreiro, A. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 269
Peroxiredoxin 1 and its role in cell signaling
Neumann, C. A., Cao, J., & Manevich, Y. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10242 · Cited by 267
Metadata
- Authors
- Backman, S. A., Ghazarian, D., So, K., Sanchez, O., Wagner, K.-U., Hennighausen, L., Suzuki, A., Tsao, M.-S., Chapman, W. B., Stambolic, V., & Mak, T. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-01-27
- Volume
- 101
- Issue
- 6
- Pages
- 1725-1730
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2149431131
- Cited by
- 159
- References
- 3
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.